Skip to search formSkip to main contentSkip to account menu

Palbociclib Isethionate

Known as: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate) 
The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

5 relations
Cyclin-Dependent KinasesGene Expression RegulationNegative Regulation of G1 PhaseNegative Regulation of G2 to M Transition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
The clinical efficacy and mechanism of Pralatrexate (PTX) combined with Palbociclib Isethionate (PAL) in the treatment of bladder… 
2016
2016
Preclinical Study of Combination of Antifolate Agents with Palbociclib Isethionate to Treat Mantle Cell Lymphoma with or without P53 Deficiency
2015
2015
Preparation method of Palbociclib isethionate
The invention belongs to the field of chemical medicine synthesis technology, and more specifically relates to a preparation… 
2014
2014
462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS.
ABSTRACT Aim: Palbociclib, a selective oral inhibitor of cyclin-dependent kinases 4 and 6, is in phase 2 and 3 clinical trials… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)